The Hygeia Group, comprising three hospitals in Athens, Greece, joins Clinerion’s hospital network, and expands Clinerion’s Patient Network Explorer footprint in Europe. The Hygeia Group comprises three hospitals:
The Hygeia Hospital is the only hospital in Greece with a Joint Commission International (JCI) Gold Seal accreditation for quality and safety in healthcare. The group currently conducts above 80 clinical trials per year. Joining Clinerion’s Patient Network Explorer platform will bring more innovative treatments to the patients of the Hygeia Group’s hospitals and clinics, and give their physicians more options in treating their patients. The group will also gain more exposure to global clinical trials run by international pharmaceutical companies and contract research organizations. Drug developers working on innovative treatments will now benefit from access to these new geographies and clinics with strong therapeutic focus. “The strong oncology orientation of our hospitals along with the high-quality oncology staff provide a great opportunity to all stakeholders to enhance clinical trials with novel agents and combinations for our patients’ benefit,” says Mr. Andreas Kartapanis, CEO of the Hygeia Group. “The Hygeia Group has state-of-the-art infrastructure and equipment, and a roster of expert clinicians,” says Ian Rentsch, CEO of Clinerion. “This will be a great benefit to pharma companies and CROs looking to accelerate their drug trials in Greece.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website:
www.clinerion.com
Clinerion’s Patient Network Explorer:
www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.